- One step back but 2 steps forward
[作者：Gribben, JG,期刊：Blood, 页码：3359-3360 , 文章类型： Editorial Material，,卷期：2009年114-16]
- In this issue of Blood, Eichhorst and colleagues report on the results of the German CLL Study Group (GCLLSG) CLL5 study. 1 The importance of this randomized trial is that it restricted enrollment to more elderly patient...
- Accumulations of KIR+ T cells in the elderly
[作者：Pawelec, G,期刊：Blood, 页码：3360-3361 , 文章类型： Editorial Material，,卷期：2009年114-16]
- Mechanisms controlling the age-associated gradual acquisition by CD8T cells of natural killer cell receptors negatively regulating lymphocyte stimulation have remained obscure. Now, data from Li and colleagues(1) imply t...
- The doctor's dilemma: stimulating T cells
[作者：Vickers, M,期刊：Blood, 页码：3361-3362 , 文章类型： Editorial Material，,卷期：2009年114-16]
- In this issue of Blood, Houot and colleagues report that T cells infiltrating human lymphomas express CD137, and that an agonistic CD137 antibody stimulates immune responses that exhibit potent activity against lymphomas...
- Through the looking glass
[作者：Alumkal, JJ,期刊：Blood, 页码：3363-3364 , 文章类型： Editorial Material，,卷期：2009年114-16]
- DNAmethylation is a common mode of gene silencing in cancer, and MDS remains the poster child for a disease in which targeting the DNMT enzymes leads to clinical benefit.(1-4) However, some important questions remain una...
- CLEC ... too!
[作者：Kunicki, TJ,期刊：Blood, 页码：3364-3365 , 文章类型： Editorial Material，,卷期：2009年114-16]
- In this issue of Blood, May and colleagues(1) demonstrate that the recently described platelet receptor CLEC-2 is important for stabilizing platelet cohesion and thrombus development under flow conditions. The absence of...
- The microenvironment in mature B-cell malignancies: a target for new treatment strategies
[作者：Burger, JA; Ghia, P; Rosenwald, A; Caligaris-Cappio, F,期刊：Blood, 页码：3367-3375 , 文章类型： Review，,卷期：2009年114-16]
- Despite major therapeutic advances, most mature B-cell malignancies remain incurable. Compelling evidence suggests that crosstalk with accessory stromal cells in specialized tissue microenvironments, such as the bone mar...
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
[作者：Eichhorst, BF; Busch, R; Stilgenbauer, S; Stauch, M; Bergmann, MA; Ritgen, M; Kranzhofer, N; Rohrberg, R; Soling, U; Burkhard, O; Westermann, A; Goede, V; Schweighofer, CD; Fischer, K; Fink, AM; Wendtner, CM; Brittinger, G; Dohner, H; Emmerich, B; Hallek, M,期刊：Blood, 页码：3382-3391 , 文章类型： Article，,卷期：2009年114-16]
- Although chronic lymphocytic leukemia (CLL) is a disease of elderly patients, subjects older than 65 years are heavily underrepresented in clinical trials. The German CLL study group (GCLLSG) initiated a multicenter phas...
- Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation
[作者：Campbell, TB; Basu, S; Hangoc, G; Tao, W; Broxmeyer, HE,期刊：Blood, 页码：3392-3401 , 文章类型： Article，,卷期：2009年114-16]
- Molecular mechanisms preserving hematopoietic stem cell (HSC) self-renewal by maintaining a balance between proliferation, differentiation, and other processes are not fully understood. Hyperactivation of the mammalian t...
- Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34(+)-derived neutrophil progenitors
[作者：Geest, CR; Buitenhuis, M; Koerkamp, MJAG; Holstege, FCP; Vellenga, E; Coffer, PJ,期刊：Blood, 页码：3402-3412 , 文章类型： Article，,卷期：2009年114-16]
- A plethora of extracellular stimuli regulate growth, survival, and differentiation responses through activation of the MEK-ERK MAPK signaling module. Using CD34(+) hematopoietic progenitor cells, we describe a novel role...
- Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease
[作者：Kukreja, A; Radfar, S; Sun, BH; Insogna, K; Dhodapkar, MV,期刊：Blood, 页码：3413-3421 , 文章类型： Article，,卷期：2009年114-16]
- Lytic bone disease in myeloma is characterized by an increase in multinucleate osteoclasts in close proximity to tumor cells. However, the nature of osteoclast precursors and the mechanisms underlying multinuclearity are...
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion
[作者：Houot, R; Goldstein, MJ; Kohrt, HE; Myklebust, JH; Alizadeh, AA; Lin, JT; Irish, JM; Torchia, JA; Kolstad, A; Chen, LP; Levy, R,期刊：Blood, 页码：3431-3438 , 文章类型： Article，,卷期：2009年114-16]
- Despite the success of passive immunotherapy with monoclonal antibodies (mAbs), many lymphoma patients eventually relapse. Induction of an adaptive immune response may elicit active and long-lasting antitumor immunity, t...
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
[作者：Parlati, F; Lee, SJ; Aujay, M; Suzuki, E; Levitsky, K; Lorens, JB; Micklem, DR; Ruurs, P; Sylvain, C; Lu, Y; Shenk, KD; Bennett, MK,期刊：Blood, 页码：3439-3447 , 文章类型： Article，,卷期：2009年114-16]
- Carfilzomib is a proteasome inhibitor in clinical development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome (c20S) and the immunoproteasome (i20S). To investigate the im...
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
[作者：Figueroa, ME; Skrabanek, L; Li, YS; Jiemjit, A; Fandy, TE; Paietta, E; Fernandez, H; Tallman, MS; Greally, JM; Carraway, H; Licht, JD; Gore, SD; Melnick, A,期刊：Blood, 页码：3448-3458 , 文章类型： Article，,卷期：2009年114-16]
- Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are res...
- Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis
[作者：Snead, JL; O'Hare, T; Adrian, LT; Eide, CA; Lange, T; Druker, BJ; Deininger, MW,期刊：Blood, 页码：3459-3463 , 文章类型： Article，,卷期：2009年114-16]
- Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm ...
|